孟鲁司特和舒利迭联合治疗中重度慢阻肺非急性发作期的效果分析(1)
[摘要] 目的 探讨孟鲁司特联合舒利迭治疗中重度慢阻肺非急性发作期的临床疗效。 方法 将122例非急性期中重度慢阻肺疾病患者随机分为观察组和对照组，每组61例，对照组给予舒利迭治疗，观察组给予孟鲁司特联合舒利迭治疗，观察两组患者治疗效果。 结果 观察组患者治疗后FVC、FEV1、FVC%均显著高于对照组(P<0.05)；观察组患者治疗后MRC评分低于对照组，ADL评分高于对照组(P<0.05)；观察组患者治疗后PH、PaO2、PaCO2指标均优于对照组(P<0.05)。 结论 孟鲁司特联合舒利迭治疗中重度慢阻肺疾病具有疗效肯定，具有较好的应用前景。
[关键词] 慢性阻塞性肺疾病；孟鲁司特；舒利迭；肺功能
[中图分类号] R563.9 [文献标识码] B [文章编号] 2095-0616(2015)16-54-03
Analysis of curative effect of montelukast combined with seretide in the treatment of non-acute attack of moderately severe COPD
, 百拇医药
LI Yonglan
Department of Pulmonary Disease， Dujiangyan Traditional Chinese Medicine Hospital， Dujiangyan 611830， China
[Abstract] Objective To explore the curative effect of montelukast combined with seretide in the treatment of non-acute attack of moderately severe COPD. Methods 122 patients with non-acute attack of moderately severe COPD were randomly allocated to an observation group of 61 patients and a control group of 61 patients. The control group was received seretide treatment， while the observation group was received montelukast combined with seretide treatment. The curative effect of two groups were observed. Results FVC， EFV1 and FVC% in observation group were all significantly higher than those in control group after treatment (P<0.05). MRC score of observation group was lower than that of control group， and ADL score was higher than that of control group (P<0.05). PH， PaO2 and PaCO2 of observation group were all better than those of control group (P<0.05). Conclusion Montelukast combined with seretide has a positive curative effect in the treatment of moderately severe COPD， which has a better prospect of application.
, 百拇医药
[Key words] COPD； Montelukast； Seretide； Pulmonary function
慢性阻塞性肺疾病(COPD)是临床常见的呼吸系统慢性疾病，是以气流受限为特征的一种炎症反应，临床表现主要为呼吸困难、咳嗽等，具有病程长、反复发作等特点[1]。本研究观察孟鲁司特与舒利迭联合治疗中重度慢阻肺非急性发作期的临床疗效，报道如下。
1 资料与方法
1.1 一般资料
研究对象共122例，均来自2012年10月～2014年10月我科收治的COPD患者，全部患者均符合2007年中国中华医学会呼吸病学分会《慢性阻塞性肺疾病的诊治指南》诊断标准[2]，均为非急性发作期患者，接受本次治疗前1周内均无合并下呼吸道感染。采取随机数字表法，将122例随机分为观察组和对照组，每组61例，观察组：男33例，女28例；年龄50～81岁，平均(65.4±8.2)岁；病程2～14年，平均(5.21±1.42)年。对照组：男34例，女27例；年龄50～80岁，平均(65.4±8.4)岁；病程2～14年，平均(5.15±1.51)年。本研究均排除伴有急性心肌梗死、肾功能衰竭、心功能衰竭等患者，两组患者分组后各基数资料比较差异无统计学意义(P>0.05)。
1.2 治疗方法
两组患者均给予沐舒坦(上海勃林格殷格翰药业有限公司，H20030360；剂量：30mg/次，3次/d，口服治疗)、缓释茶碱(北京紫竹药业有限公司，H1020150；剂量：0.1g，2次/d，口服治疗)等基础治疗，对照组在此基础上给予舒利迭(沙美特罗/丙酸氟替卡松，50μg/250μg；葛兰素威康英国公司；H20090241)吸入治疗，2次/d，早晚各1次。观察组在对照组治疗基础上加用孟鲁司特(杭州默沙东制药有限公司；J20070058)口服治疗，剂量：10mg/次，1次每晚。两组患者治疗12周为1疗程，2个疗程后进行疗效评价。, 百拇医药(李永兰)
[关键词] 慢性阻塞性肺疾病；孟鲁司特；舒利迭；肺功能
[中图分类号] R563.9 [文献标识码] B [文章编号] 2095-0616(2015)16-54-03
Analysis of curative effect of montelukast combined with seretide in the treatment of non-acute attack of moderately severe COPD
, 百拇医药
LI Yonglan
Department of Pulmonary Disease， Dujiangyan Traditional Chinese Medicine Hospital， Dujiangyan 611830， China
[Abstract] Objective To explore the curative effect of montelukast combined with seretide in the treatment of non-acute attack of moderately severe COPD. Methods 122 patients with non-acute attack of moderately severe COPD were randomly allocated to an observation group of 61 patients and a control group of 61 patients. The control group was received seretide treatment， while the observation group was received montelukast combined with seretide treatment. The curative effect of two groups were observed. Results FVC， EFV1 and FVC% in observation group were all significantly higher than those in control group after treatment (P<0.05). MRC score of observation group was lower than that of control group， and ADL score was higher than that of control group (P<0.05). PH， PaO2 and PaCO2 of observation group were all better than those of control group (P<0.05). Conclusion Montelukast combined with seretide has a positive curative effect in the treatment of moderately severe COPD， which has a better prospect of application.
, 百拇医药
[Key words] COPD； Montelukast； Seretide； Pulmonary function
慢性阻塞性肺疾病(COPD)是临床常见的呼吸系统慢性疾病，是以气流受限为特征的一种炎症反应，临床表现主要为呼吸困难、咳嗽等，具有病程长、反复发作等特点[1]。本研究观察孟鲁司特与舒利迭联合治疗中重度慢阻肺非急性发作期的临床疗效，报道如下。
1 资料与方法
1.1 一般资料
研究对象共122例，均来自2012年10月～2014年10月我科收治的COPD患者，全部患者均符合2007年中国中华医学会呼吸病学分会《慢性阻塞性肺疾病的诊治指南》诊断标准[2]，均为非急性发作期患者，接受本次治疗前1周内均无合并下呼吸道感染。采取随机数字表法，将122例随机分为观察组和对照组，每组61例，观察组：男33例，女28例；年龄50～81岁，平均(65.4±8.2)岁；病程2～14年，平均(5.21±1.42)年。对照组：男34例，女27例；年龄50～80岁，平均(65.4±8.4)岁；病程2～14年，平均(5.15±1.51)年。本研究均排除伴有急性心肌梗死、肾功能衰竭、心功能衰竭等患者，两组患者分组后各基数资料比较差异无统计学意义(P>0.05)。
1.2 治疗方法
两组患者均给予沐舒坦(上海勃林格殷格翰药业有限公司，H20030360；剂量：30mg/次，3次/d，口服治疗)、缓释茶碱(北京紫竹药业有限公司，H1020150；剂量：0.1g，2次/d，口服治疗)等基础治疗，对照组在此基础上给予舒利迭(沙美特罗/丙酸氟替卡松，50μg/250μg；葛兰素威康英国公司；H20090241)吸入治疗，2次/d，早晚各1次。观察组在对照组治疗基础上加用孟鲁司特(杭州默沙东制药有限公司；J20070058)口服治疗，剂量：10mg/次，1次每晚。两组患者治疗12周为1疗程，2个疗程后进行疗效评价。, 百拇医药(李永兰)